Current News from our Company

Virion\Serion proudly announces the launch of our new Dengue Virus Type 2 Envelope Protein E (BA114R01), West Nile Virus Envelope Protein E (BA141R01) and West Nile Virus 6His-4ED3 Antigen (BA141VSR14).

Our latest SERION antigens designed for superior performance

Tailored Antigens for Highest CLIA Assay Performance - Recombinant Measles, Mumps, Rubella & Varicella Antigens.

SERION Immunologics Measles Virus Antigen - Premium was successfully applied in in-vitro stimulation assays to assess anti-tumor immunity induced by virotherapy.

A new microarray for the determination of a patient's vaccination status was developed by the InfectoGnostics Research Campus Jena.

Effecient removal of IgG antbodies for reliable IgM detection.

We are very pleased to inform you that the portfolio of SERION antigens is expanding further by the addition of a new recombinant VZV antigen.